Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
32
RGNX Quote, Financials, Valuation and Earnings
Last price:
$8.14
Seasonality move
:
4.61%
Day range:
$8.04 - $8.83
52-week range:
$5.04 - $16.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.58x
P/B ratio:
2.55x
Volume:
1M
Avg. volume:
1.1M
1-year change:
10.6%
Market cap:
$412.1M
Revenue:
$83.3M
EPS (TTM):
-$3.49
Analysts' Opinion
-
Consensus RatingREGENXBIO, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.18, REGENXBIO, Inc. has an estimated upside of 258.5% from its current price of $8.14.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $8.14.
Fair Value
-
According to the consensus of 7 analysts, REGENXBIO, Inc. has 258.5% upside to fair value with a price target of $29.18 per share.
RGNX vs. S&P 500
-
Over the past 5 trading days, REGENXBIO, Inc. has underperformed the S&P 500 by -3.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
REGENXBIO, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
REGENXBIO, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter REGENXBIO, Inc. reported revenues of $29.7M.
Earnings Growth
-
REGENXBIO, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter REGENXBIO, Inc. reported earnings per share of -$1.20.
Enterprise value:
406M
EV / Invested capital:
--
Price / LTM sales:
2.58x
EV / EBIT:
--
EV / Revenue:
2.52x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.82x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$124.9M
Return On Assets:
-34.45%
Net Income Margin (TTM):
-110.29%
Return On Equity:
-73.5%
Return On Invested Capital:
-40.97%
Operating Margin:
-176.27%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $99.4M | $84.3M | $161.3M | $24.2M | $29.7M | |
| Gross Profit | $43.5M | $29.3M | $124.9M | $7.8M | $20.1M | |
| Operating Income | -$262M | -$243.8M | -$154.9M | -$62.1M | -$52.4M | |
| EBITDA | -$244.9M | -$227.3M | -$139.2M | -$58.1M | -$48.5M | |
| Diluted EPS | -$5.98 | -$5.03 | -$3.49 | -$1.17 | -$1.20 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $410.2M | $436.6M | $365.8M | $313.4M | $332M | |
| Total Assets | $800.4M | $883.8M | $633.8M | $519.1M | $525.2M | |
| Current Liabilities | $106.8M | $123.5M | $127.3M | $102.7M | $124.6M | |
| Total Liabilities | $339M | $320M | $270.7M | $217.7M | $363.8M | |
| Total Equity | $461.4M | $563.8M | $363.1M | $301.4M | $161.5M | |
| Total Debt | $83.9M | $84.7M | $84.1M | $138.1M | $259.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$217M | -$182.3M | -$103.3M | -$40.5M | -$56M | |
| Cash From Investing | $183.7M | $97.1M | -$13.1M | $50.3M | $42.3M | |
| Cash From Financing | -$31.9M | $88.5M | $118.6M | -$10.9M | -$7.1M | |
| Free Cash Flow | -$231.3M | -$184.7M | -$106.3M | -$40.9M | -$56.5M | |
RGNX
Sector
Market Cap
$412.1M
$25.6M
Price % of 52-Week High
50.28%
49.47%
Dividend Yield
0%
0%
Shareholder Yield
-34.23%
-1.77%
1-Year Price Total Return
10.6%
-21.96%
Beta (5-Year)
1.052
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.27
200-day SMA
Sell
Level
$10.55
Bollinger Bands (100)
Sell
Level
10.39 - 14.11
Chaikin Money Flow
Sell
Level
-334.5K
20-day SMA
Sell
Level
$10.21
Relative Strength Index (RSI14)
Sell
Level
29.04
ADX Line
Buy
Level
11.14
Williams %R
Buy
Level
-85.7143
50-day SMA
Sell
Level
$12.61
MACD (12, 26)
Buy
Level
1.54
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Sell
Level
-701.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.6954)
Sell
CA Score
(Annual)
Level (-2.1807)
Buy
Beneish M-Score
(Annual)
Level (-3.2382)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.1091)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Stock Forecast FAQ
In the current month, RGNX has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RGNX average analyst price target in the past 3 months is $29.18.
-
Where Will REGENXBIO, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that REGENXBIO, Inc. share price will rise to $29.18 per share over the next 12 months.
-
What Do Analysts Say About REGENXBIO, Inc.?
Analysts are divided on their view about REGENXBIO, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that REGENXBIO, Inc. is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is REGENXBIO, Inc.'s Price Target?
The price target for REGENXBIO, Inc. over the next 1-year time period is forecast to be $29.18 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RGNX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for REGENXBIO, Inc. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RGNX?
You can purchase shares of REGENXBIO, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase REGENXBIO, Inc. shares.
-
What Is The REGENXBIO, Inc. Share Price Today?
REGENXBIO, Inc. was last trading at $8.14 per share. This represents the most recent stock quote for REGENXBIO, Inc.. Yesterday, REGENXBIO, Inc. closed at $8.14 per share.
-
How To Buy REGENXBIO, Inc. Stock Online?
In order to purchase REGENXBIO, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RGNX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RGNX
Sector
P/E ratio
--
23.36x
PEG ratio
--
-0.01x
P/B ratio
2.55x
1.78x
Price / LTM sales
2.58x
1.56x
Growth Metrics
RGNX
Sector
Revenue growth
22.88%
3.51%
Earnings growth
-2.14%
9.66%
Revenue (5-year growth)
18.79%
6.45%
Earnings forecast
-$0.84
-$0.19
Profitability
RGNX
Sector
Profitability FY 2024
$33.5M
$2.6M
Return on invested capital
-40.97%
-33.43%
Return on assets
-34.45%
-29.68%
Return on equity
-73.5%
-38.71%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
5
Balance Sheet
RGNX
Sector
Total cash
$274.2M
$25M
Short term investments
$177.2M
$24M
Total assets
$466M
$71.9M
Long term debt
$259.1M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
